Summary In this episode of the Med City Pivot Podcast, host Arundhati Parmar speaks with Lars Petersen about one of the most remarkable corporate transformations in modern business history.
Facing a catastrophic collapse of its core film business in the mid-2000s due to the rise of digital photography, Fujifilm executed a bold and strategic pivot into healthcare and life sciences. The company diversified aggressively, leveraging its deep expertise in materials science, imaging, and innovation to build a thriving biotechnology and medical technology ecosystem.
Today, Fujifilm operates as a global Contract Development and Manufacturing Organization (CDMO), partnering with leading pharmaceutical companies and startups alike. The conversation explores how strategic investment, diversification, long-term thinking, and innovation—including AI—enabled Fujifilm not just to survive, but to lead in a completely new industry.
Links & Resources * Connect with Arundhati Parmar * aparmar@medcitynews.com * https://twitter.com/aparmarbb?lang=en * https://medcitynews.com/
Keywords Fujifilm Pivot Healthcare CDMO Biotechnology Biologics digital transformation business strategy Innovation AI in healthcare Pharma Manufacturing monoclonal antibodies gene therapy cell therapy Diversification corporate strategy MedTech
Episode Highlights * 00:00–00:23 – Introduction to the concept of "pivot" and Fujifilm's survival story * 00:00–00:47 – The collapse of the film industry and existential crisis * 00:00–01:15 – Fujifilm's transformation into a healthcare company * 00:02:39–00:03:28 – 2006: the pivotal year and 60% revenue loss * 00:03:28–00:03:45 – Strategic decision to diversify long-term * 00:04:22–00:05:08 – Why Fujifilm succeeded while competitors failed * 00:05:35–00:06:26 – Key investments and acquisitions (including Biogen assets) * 00:06:52–00:07:30 – Why healthcare is a stable, long-term growth industry * 00:07:53–00:08:29 – Expansion into medical devices and imaging technologies * 00:09:42–00:10:34 – Core therapeutic focus: biologics, gene therapy, cell therapy * 00:10:49–00:11:22 – Serving both startups and global pharma giants * 00:12:39–00:13:40 – Competitive positioning vs. Samsung Biologics & Lonza * 00:15:08–00:15:44 – "Partners for life" philosophy and long-term trust * 00:17:52–00:18:49 – AI integration across manufacturing ecosystems * 00:18:54–00:19:42 – Final takeaway: building shared ecosystems for the future of medicine